pharma · Infertility in women undergoing assisted reproductive technologies (ART) · Intermediate risk, non-muscle invasive bladder cancer
Ferring Pharmaceuticals
Ferring Pharmaceuticals clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- -, St-Prex, 1162, CH, Mumbai
- Founded
- 1950
- Employees
- 6,228
- Programs
- 13
- Drugs
- 23
- Patents
- 0
Ferring Pharmaceuticals projects
6 ClinicalTrials.gov programs sponsored by Ferring Pharmaceuticals.
Ferring Pharmaceuticals has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
000434
Ferring Pharmaceuticals
High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ(CIS) with or without papillary tumours
1 trial -
ADSTILADRIN
Ferring Pharmaceuticals
Intermediate risk, non-muscle invasive bladder cancer
1 trial -
Desmopressin
Ferring Pharmaceuticals
Nocturia
1 trial -
FE 999326
Ferring Pharmaceuticals
Bladder Cancer
1 trial -
FE 999913 vaginal tablet
Ferring Pharmaceuticals
Luteal Hormone Supplementation
1 trial -
Follitropin alfa
Ferring Pharmaceuticals
Controlled Ovarian Simulation
1 trial
Frequently asked questions
How many clinical projects does Ferring Pharmaceuticals have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.